Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer

16 Aug 2025

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype associated with the highest mortality rate among all breast cancer subtypes, primarily due to the absence of actionable therapeutic targets. Although poly (ADP-ribose) polymerase inhibitors (PARPi) have shown promising therapeutic effects in TNBC patients harboring homologous recombination deficiency (HRD), their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40819058
DOI: 10.1186/s12943-025-02422-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancerPMID 40819058Read ↗

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read ↗

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiencySemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

DNA damage response in breast cancer and its significant role in guiding novel precise therapiesSemantic proximity Read ↗

Targeting the DNA repair pathway for breast cancer therapy: Beyond the molecular subtypesSemantic proximity Read ↗

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expressionSemantic proximity Read ↗

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast CancerSemantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Exploiting DNA repair defects in triple negative breast cancer to improve cell killingSemantic proximity Read ↗

Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.Semantic proximity Read ↗

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.